NICE backs Takeda’s Alunbrig in second-line lung cancerNICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive Share XNICE backs Takeda’s Alunbrig in second-line lung cancerhttps://pharmaphorum.com/news/nice-backs-takedas-alunbrig-in-second-line-lung-cancer/
Statins could protect against motor neurone disease, scientists suggestHigh cholesterol could be a risk factor in development of motor neurone disease, according to a study of Share XStatins could protect against motor neurone disease, scientists suggesthttps://pharmaphorum.com/news/statins-could-protect-against-motor-neurone-disease-scientists-suggest/
Rap video is latest evidence in Insys trialA rap video used to motivate Insys Therapeutics’ salesforce into promoting higher doses of its opioid drug Subsys Share XRap video is latest evidence in Insys trialhttps://pharmaphorum.com/news/rap-video-is-latest-evidence-in-insys-trial/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
Price cut unlocks NICE nod for Perjeta in post-surgery breast cancerRoche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer Share XPrice cut unlocks NICE nod for Perjeta in post-surgery breast cancerhttps://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/
AZ’s CEO dismisses “fake news” about his imminent departureAstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced Share XAZ’s CEO dismisses “fake news” about his imminent departurehttps://pharmaphorum.com/news/azs-ceo-dismisses-fake-news-about-his-imminent-departure/
Harpoon and Gossamer sneak out IPOs before potential SEC shutdownImmunotherapy specialist Harpoon Therapeutics has joined a group of biotechs that have sneaked out IPOs before another potential Share XHarpoon and Gossamer sneak out IPOs before potential SEC shutdownhttps://pharmaphorum.com/news/harpoon-and-gossamer-sneak-out-ipos-before-potential-sec-shutdown/
WHO discusses digital health roadmap for EuropeThe World Health Organisation has opened discussions into a roadmap for accelerating the digitisation of health systems in Share XWHO discusses digital health roadmap for Europehttps://pharmaphorum.com/news/who-digital-health-roadmap-europe/
Chinese patients to get new drugs before UK after Brexit – says CEOUS, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, Share XChinese patients to get new drugs before UK after Brexit – says CEOhttps://pharmaphorum.com/news/chinese-patients-new-drugs-before-uk-brexit-ceo/
